These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

169 related articles for article (PubMed ID: 37966111)

  • 1. Antitumor activity of AZD0754, a dnTGFβRII-armored, STEAP2-targeted CAR-T cell therapy, in prostate cancer.
    Zanvit P; van Dyk D; Fazenbaker C; McGlinchey K; Luo W; Pezold JM; Meekin J; Chang CY; Carrasco RA; Breen S; Cheung CS; Endlich-Frazier A; Clark B; Chu NJ; Vantellini A; Martin PL; Hoover CE; Riley K; Sweet SM; Chain D; Kim YJ; Tu E; Harder N; Phipps S; Damschroder M; Gilbreth RN; Cobbold M; Moody G; Bosco EE
    J Clin Invest; 2023 Nov; 133(22):. PubMed ID: 37966111
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Armored bicistronic CAR T cells with dominant-negative TGF-β receptor II to overcome resistance in glioblastoma.
    Li N; Rodriguez JL; Yin Y; Logun MT; Zhang L; Yu S; Hicks KA; Zhang JV; Zhang L; Xie C; Wang J; Wang T; Xu J; Fraietta JA; Binder ZA; Lin Z; O'Rourke DM
    Mol Ther; 2024 Oct; 32(10):3522-3538. PubMed ID: 39086131
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Anti-PSMA CAR-engineered NK-92 Cells: An Off-the-shelf Cell Therapy for Prostate Cancer.
    Montagner IM; Penna A; Fracasso G; Carpanese D; Dalla Pietà A; Barbieri V; Zuccolotto G; Rosato A
    Cells; 2020 Jun; 9(6):. PubMed ID: 32498368
    [TBL] [Abstract][Full Text] [Related]  

  • 4. PSMA-targeting TGFβ-insensitive armored CAR T cells in metastatic castration-resistant prostate cancer: a phase 1 trial.
    Narayan V; Barber-Rotenberg JS; Jung IY; Lacey SF; Rech AJ; Davis MM; Hwang WT; Lal P; Carpenter EL; Maude SL; Plesa G; Vapiwala N; Chew A; Moniak M; Sebro RA; Farwell MD; Marshall A; Gilmore J; Lledo L; Dengel K; Church SE; Hether TD; Xu J; Gohil M; Buckingham TH; Yee SS; Gonzalez VE; Kulikovskaya I; Chen F; Tian L; Tien K; Gladney W; Nobles CL; Raymond HE; ; Hexner EO; Siegel DL; Bushman FD; June CH; Fraietta JA; Haas NB
    Nat Med; 2022 Apr; 28(4):724-734. PubMed ID: 35314843
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Efficacy Against Human Prostate Cancer by Prostate-specific Membrane Antigen-specific, Transforming Growth Factor-β Insensitive Genetically Targeted CD8
    Zhang Q; Helfand BT; Carneiro BA; Qin W; Yang XJ; Lee C; Zhang W; Giles FJ; Cristofanilli M; Kuzel TM
    Eur Urol; 2018 May; 73(5):648-652. PubMed ID: 29275833
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Intrinsic ADRB2 inhibition improves CAR-T cell therapy efficacy against prostate cancer.
    Ajmal I; Farooq MA; Duan Y; Yao J; Gao Y; Hui X; Ge Y; Chen Y; Ren Y; Du B; Jiang W
    Mol Ther; 2024 Oct; 32(10):3539-3557. PubMed ID: 39228124
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Dominant-Negative TGF-β Receptor Enhances PSMA-Targeted Human CAR T Cell Proliferation And Augments Prostate Cancer Eradication.
    Kloss CC; Lee J; Zhang A; Chen F; Melenhorst JJ; Lacey SF; Maus MV; Fraietta JA; Zhao Y; June CH
    Mol Ther; 2018 Jul; 26(7):1855-1866. PubMed ID: 29807781
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Engineering Cancer Antigen-Specific T Cells to Overcome the Immunosuppressive Effects of TGF-β.
    Silk JD; Abbott RJM; Adams KJ; Bennett AD; Brett S; Cornforth TV; Crossland KL; Figueroa DJ; Jing J; O'Connor C; Pachnio A; Patasic L; Peredo CE; Quattrini A; Quinn LL; Rust AG; Saini M; Sanderson JP; Steiner D; Tavano B; Viswanathan P; Wiedermann GE; Wong R; Jakobsen BK; Britten CM; Gerry AB; Brewer JE
    J Immunol; 2022 Jan; 208(1):169-180. PubMed ID: 34853077
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Targeting advanced prostate cancer with STEAP1 chimeric antigen receptor T cell and tumor-localized IL-12 immunotherapy.
    Bhatia V; Kamat NV; Pariva TE; Wu LT; Tsao A; Sasaki K; Sun H; Javier G; Nutt S; Coleman I; Hitchcock L; Zhang A; Rudoy D; Gulati R; Patel RA; Roudier MP; True LD; Srivastava S; Morrissey CM; Haffner MC; Nelson PS; Priceman SJ; Ishihara J; Lee JK
    Nat Commun; 2023 Apr; 14(1):2041. PubMed ID: 37041154
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Construction of a chimeric antigen receptor bearing a nanobody against prostate a specific membrane antigen in prostate cancer.
    Hassani M; Hajari Taheri F; Sharifzadeh Z; Arashkia A; Hadjati J; van Weerden WM; Modarressi MH; Abolhassani M
    J Cell Biochem; 2019 Jun; 120(6):10787-10795. PubMed ID: 30672018
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Chimeric cytokine receptor enhancing PSMA-CAR-T cell-mediated prostate cancer regression.
    Weimin S; Abula A; Qianghong D; Wenguang W
    Cancer Biol Ther; 2020 Jun; 21(6):570-580. PubMed ID: 32208880
    [No Abstract]   [Full Text] [Related]  

  • 12. Armored BCMA CAR T Cells Eliminate Multiple Myeloma and Are Resistant to the Suppressive Effects of TGF-β.
    Alabanza LM; Xiong Y; Vu B; Webster B; Wu D; Hu P; Zhu Z; Dropulic B; Dash P; Schneider D
    Front Immunol; 2022; 13():832645. PubMed ID: 35222421
    [TBL] [Abstract][Full Text] [Related]  

  • 13. PTK7-Targeting CAR T-Cells for the Treatment of Lung Cancer and Other Malignancies.
    Jie Y; Liu G; Feng L; Li Y; E M; Wu L; Li Y; Rong G; Li Y; Wei H; Gu A
    Front Immunol; 2021; 12():665970. PubMed ID: 34475869
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Dominant-negative transforming growth factor-β receptor-armoured mesothelin-targeted chimeric antigen receptor T cells slow tumour growth in a mouse model of ovarian cancer.
    Li K; Xu J; Wang J; Lu C; Dai Y; Dai Q; Zhang W; Xu C; Wu S; Kang Y
    Cancer Immunol Immunother; 2023 Apr; 72(4):917-928. PubMed ID: 36166071
    [TBL] [Abstract][Full Text] [Related]  

  • 15. High-throughput method to analyze the cytotoxicity of CAR-T Cells in a 3D tumor spheroid model using image cytometry.
    Zurowski D; Patel S; Hui D; Ka M; Hernandez C; Love AC; Lin B; Moore A; Chan LL
    SLAS Discov; 2023 Apr; 28(3):65-72. PubMed ID: 36758833
    [TBL] [Abstract][Full Text] [Related]  

  • 16. CAR T Cells Targeting MISIIR for the Treatment of Ovarian Cancer and Other Gynecologic Malignancies.
    Rodriguez-Garcia A; Sharma P; Poussin M; Boesteanu AC; Minutolo NG; Gitto SB; Omran DK; Robinson MK; Adams GP; Simpkins F; Powell DJ
    Mol Ther; 2020 Feb; 28(2):548-560. PubMed ID: 31870622
    [TBL] [Abstract][Full Text] [Related]  

  • 17. TGF-β/IL-7 Chimeric Switch Receptor-Expressing CAR-T Cells Inhibit Recurrence of CD19-Positive B Cell Lymphoma.
    Noh KE; Lee JH; Choi SY; Jung NC; Nam JH; Oh JS; Song JY; Seo HG; Wang Y; Lee HS; Lim DS
    Int J Mol Sci; 2021 Aug; 22(16):. PubMed ID: 34445415
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Inducible localized delivery of an anti-PD-1 scFv enhances anti-tumor activity of ROR1 CAR-T cells in TNBC.
    Harrasser M; Gohil SH; Lau H; Della Peruta M; Muczynski V; Patel D; Miranda E; Grigoriadis K; Grigoriadis A; Granger D; Evans R; Nathwani AC
    Breast Cancer Res; 2022 Jun; 24(1):39. PubMed ID: 35659040
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Preclinical Evaluation of Chimeric Antigen Receptor-Modified T Cells Specific to Epithelial Cell Adhesion Molecule for Treating Colorectal Cancer.
    Zhang BL; Li D; Gong YL; Huang Y; Qin DY; Jiang L; Liang X; Yang X; Gou HF; Wang YS; Wei YQ; Wang W
    Hum Gene Ther; 2019 Apr; 30(4):402-412. PubMed ID: 30693795
    [TBL] [Abstract][Full Text] [Related]  

  • 20. SMAD7 expression in CAR-T cells improves persistence and safety for solid tumors.
    Liang S; Zheng R; Zuo B; Li J; Wang Y; Han Y; Dong H; Zhao X; Zhang Y; Wang P; Meng R; Jia L; Yang A; Yan B
    Cell Mol Immunol; 2024 Mar; 21(3):213-226. PubMed ID: 38177245
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.